Chapter/Section Purchase

1 Study Coverage
1.1 Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2017-2022) & (US$ Million) Introduction
1.2 Global Non-infectious Macular Edema Treatment Outlook 2017 VS 2022 VS 2028
1.2.1 Global Non-infectious Macular Edema Treatment Market Size for the Year 2017-2028
1.2.2 Global Non-infectious Macular Edema Treatment Market Size for the Year 2017-2028
1.3 Non-infectious Macular Edema Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Non-infectious Macular Edema Treatment in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Non-infectious Macular Edema Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Non-infectious Macular Edema Treatment Market Dynamics
1.4.1 Non-infectious Macular Edema Treatment Industry Trends
1.4.2 Non-infectious Macular Edema Treatment Market Drivers
1.4.3 Non-infectious Macular Edema Treatment Market Challenges
1.4.4 Non-infectious Macular Edema Treatment Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Non-infectious Macular Edema Treatment by Type
2.1 Non-infectious Macular Edema Treatment Market Segment by Type
2.1.1 Anti-VEGF Therapy
2.1.2 Corticosteroid
2.1.3 Immune Inhibitor
2.1.4 Biological Preparation
2.1.5 Other
2.2 Global Non-infectious Macular Edema Treatment Market Size by Type (2017, 2022 & 2028)
2.3 Global Non-infectious Macular Edema Treatment Market Size by Type (2017-2028)
2.4 United States Non-infectious Macular Edema Treatment Market Size by Type (2017, 2022 & 2028)
2.5 United States Non-infectious Macular Edema Treatment Market Size by Type (2017-2028)
3 Non-infectious Macular Edema Treatment by Application
3.1 Non-infectious Macular Edema Treatment Market Segment by Application
3.1.1 Retail Pharmacy
3.1.2 Hospital Pharmacy
3.1.3 Other
3.2 Global Non-infectious Macular Edema Treatment Market Size by Application (2017, 2022 & 2028)
3.3 Global Non-infectious Macular Edema Treatment Market Size by Application (2017-2028)
3.4 United States Non-infectious Macular Edema Treatment Market Size by Application (2017, 2022 & 2028)
3.5 United States Non-infectious Macular Edema Treatment Market Size by Application (2017-2028)
4 Global Non-infectious Macular Edema Treatment Competitor Landscape by Company
4.1 Global Non-infectious Macular Edema Treatment Market Size by Company
4.1.1 Top Global Non-infectious Macular Edema Treatment Companies Ranked by Revenue (2021)
4.1.2 Global Non-infectious Macular Edema Treatment Revenue by Player (2017-2022)
4.2 Global Non-infectious Macular Edema Treatment Concentration Ratio (CR)
4.2.1 Non-infectious Macular Edema Treatment Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Non-infectious Macular Edema Treatment in 2021
4.2.3 Global Non-infectious Macular Edema Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Non-infectious Macular Edema Treatment Headquarters, Revenue in Non-infectious Macular Edema Treatment Business (2017-2022) & (US$ Million) Type
4.3.1 Global Non-infectious Macular Edema Treatment Headquarters and Area Served
4.3.2 Global Non-infectious Macular Edema Treatment Companies Revenue in Non-infectious Macular Edema Treatment Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Non-infectious Macular Edema Treatment Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Non-infectious Macular Edema Treatment Market Size by Company
4.5.1 Top Non-infectious Macular Edema Treatment Players in United States, Ranked by Revenue (2021)
4.5.2 United States Non-infectious Macular Edema Treatment Revenue by Players (2020, 2021 & 2022)
5 Global Non-infectious Macular Edema Treatment Market Size by Region
5.1 Global Non-infectious Macular Edema Treatment Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Non-infectious Macular Edema Treatment Market Size by Region (2017-2028)
5.2.1 Global Non-infectious Macular Edema Treatment Market Size by Region: 2017-2022
5.2.2 Global Non-infectious Macular Edema Treatment Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Non-infectious Macular Edema Treatment Market Size YoY Growth 2017-2028
6.1.2 North America Non-infectious Macular Edema Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Non-infectious Macular Edema Treatment Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Non-infectious Macular Edema Treatment Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Non-infectious Macular Edema Treatment Market Size YoY Growth 2017-2028
6.3.2 Europe Non-infectious Macular Edema Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Non-infectious Macular Edema Treatment Market Size YoY Growth 2017-2028
6.4.2 Latin America Non-infectious Macular Edema Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Non-infectious Macular Edema Treatment Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Non-infectious Macular Edema Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Allergan
7.1.1 Allergan Company Details
7.1.2 Allergan Business Overview
7.1.3 Allergan Non-infectious Macular Edema Treatment Introduction
7.1.4 Allergan Revenue in Non-infectious Macular Edema Treatment Business (2017-2022)
7.1.5 Allergan Recent Development
7.2 Amgen
7.2.1 Amgen Company Details
7.2.2 Amgen Business Overview
7.2.3 Amgen Non-infectious Macular Edema Treatment Introduction
7.2.4 Amgen Revenue in Non-infectious Macular Edema Treatment Business (2017-2022)
7.2.5 Amgen Recent Development
7.3 Pfizer
7.3.1 Pfizer Company Details
7.3.2 Pfizer Business Overview
7.3.3 Pfizer Non-infectious Macular Edema Treatment Introduction
7.3.4 Pfizer Revenue in Non-infectious Macular Edema Treatment Business (2017-2022)
7.3.5 Pfizer Recent Development
7.4 Novartis AG
7.4.1 Novartis AG Company Details
7.4.2 Novartis AG Business Overview
7.4.3 Novartis AG Non-infectious Macular Edema Treatment Introduction
7.4.4 Novartis AG Revenue in Non-infectious Macular Edema Treatment Business (2017-2022)
7.4.5 Novartis AG Recent Development
7.5 F. Hoffman-La Roche
7.5.1 F. Hoffman-La Roche Company Details
7.5.2 F. Hoffman-La Roche Business Overview
7.5.3 F. Hoffman-La Roche Non-infectious Macular Edema Treatment Introduction
7.5.4 F. Hoffman-La Roche Revenue in Non-infectious Macular Edema Treatment Business (2017-2022)
7.5.5 F. Hoffman-La Roche Recent Development
7.6 AbbVie
7.6.1 AbbVie Company Details
7.6.2 AbbVie Business Overview
7.6.3 AbbVie Non-infectious Macular Edema Treatment Introduction
7.6.4 AbbVie Revenue in Non-infectious Macular Edema Treatment Business (2017-2022)
7.6.5 AbbVie Recent Development
7.7 Bayer AG
7.7.1 Bayer AG Company Details
7.7.2 Bayer AG Business Overview
7.7.3 Bayer AG Non-infectious Macular Edema Treatment Introduction
7.7.4 Bayer AG Revenue in Non-infectious Macular Edema Treatment Business (2017-2022)
7.7.5 Bayer AG Recent Development
7.8 Valeant Pharmaceuticals
7.8.1 Valeant Pharmaceuticals Company Details
7.8.2 Valeant Pharmaceuticals Business Overview
7.8.3 Valeant Pharmaceuticals Non-infectious Macular Edema Treatment Introduction
7.8.4 Valeant Pharmaceuticals Revenue in Non-infectious Macular Edema Treatment Business (2017-2022)
7.8.5 Valeant Pharmaceuticals Recent Development
7.9 Alimera Sciences
7.9.1 Alimera Sciences Company Details
7.9.2 Alimera Sciences Business Overview
7.9.3 Alimera Sciences Non-infectious Macular Edema Treatment Introduction
7.9.4 Alimera Sciences Revenue in Non-infectious Macular Edema Treatment Business (2017-2022)
7.9.5 Alimera Sciences Recent Development
7.10 Clearside Biomedical
7.10.1 Clearside Biomedical Company Details
7.10.2 Clearside Biomedical Business Overview
7.10.3 Clearside Biomedical Non-infectious Macular Edema Treatment Introduction
7.10.4 Clearside Biomedical Revenue in Non-infectious Macular Edema Treatment Business (2017-2022)
7.10.5 Clearside Biomedical Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer